Work

Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial

Year: 2014

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2014-ct236

Authors: Gerald S. Falchook, David S. Hong, Hesham M. Amin, Siqing Fu, Sarina Anne Piha-Paul, Filip Janku, J. Gabrielle Granda, HongXia Zheng, Manfred B. Klevesath, Karola Köhler, Friedhelm Bladt, Andreas Johne, Razelle Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), University of California San Diego, Moores Cancer Center

Language: English

Topic: Cancer Mechanisms and Therapy

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2048417500

Cites:

Cited by: 1

Related to: 10